NCT07011771View on ClinicalTrials.gov

A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

November 30, 2029

Conditions
GBA1 Parkinson Disease
Interventions
DRUG

gene therapy

IV gene therapy

DRUG

gene therapy

IV gene therapy

Trial Locations (6)

10032

New York Presbyterian Hospital-Columbia University Medical Center, New York

19104

University of Pennsylvania, Philadelphia

60612

Rush University Medical Center, Chicago

77030

Baylor College of Medicine, Houston

98034

Booth Gardner Parkinson's Care Center - Evergreen Neuroscience Institute, Kirkland

99202

Inland Northwest Research, Spokane

Sponsors
All Listed Sponsors
lead

Capsida Biotherapeutics, Inc.

INDUSTRY